Literature DB >> 34371831

Food Enrichment with Glycyrrhiza glabra Extract Suppresses ACE2 mRNA and Protein Expression in Rats-Possible Implications for COVID-19.

Daniela Jezova1, Peter Karailiev1, Lucia Karailievova1, Agnesa Puhova1, Harald Murck2,3.   

Abstract

Angiotensin converting enzyme 2 (ACE2) is a key entry point of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus known to induce Coronavirus disease 2019 (COVID-19). We have recently outlined a concept to reduce ACE2 expression by the administration of glycyrrhizin, a component of Glycyrrhiza glabra extract, via its inhibitory activity on 11beta hydroxysteroid dehydrogenase type 2 (11betaHSD2) and resulting activation of mineralocorticoid receptor (MR). We hypothesized that in organs such as the ileum, which co-express 11betaHSD2, MR and ACE2, the expression of ACE2 would be suppressed. We studied organ tissues from an experiment originally designed to address the effects of Glycyrrhiza glabra extract on stress response. Male Sprague Dawley rats were left undisturbed or exposed to chronic mild stress for five weeks. For the last two weeks, animals continued with a placebo diet or received a diet containing extract of Glycyrrhiza glabra root at a dose of 150 mg/kg of body weight/day. Quantitative PCR measurements showed a significant decrease in gene expression of ACE2 in the small intestine of rats fed with diet containing Glycyrrhiza glabra extract. This effect was independent of the stress condition and failed to be observed in non-target tissues, namely the heart and the brain cortex. In the small intestine we also confirmed the reduction of ACE2 at the protein level. Present findings provide evidence to support the hypothesis that Glycyrrhiza glabra extract may reduce an entry point of SARS-CoV-2. Whether this phenomenon, when confirmed in additional studies, is linked to the susceptibility of cells to the virus requires further studies.

Entities:  

Keywords:  COVID-19; aldosterone; angiotensin converting enzyme; glycyrrhizin; mineralocorticoid receptor; toll like receptor 4

Year:  2021        PMID: 34371831     DOI: 10.3390/nu13072321

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  6 in total

1.  An In-vitro evaluation of a polyherbal formulation, against SARS-Cov-2.

Authors:  Divya Kanchibhotla; Saumya Subramanian; Reddy M Ravi Kumar; K R Venkatesh Hari; Monika Pathania
Journal:  J Ayurveda Integr Med       Date:  2022-06-23

2.  Preventing the Adverse Effects of SARS-CoV-2 Infection and COVID-19 through Diet, Supplements, and Lifestyle.

Authors:  Ronan Lordan; William B Grant
Journal:  Nutrients       Date:  2021-12-28       Impact factor: 5.717

Review 3.  Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: Potential pharmacological applications with mechanistic insight.

Authors:  Dheeraj Bisht; Mohmmad Rashid; Rajeshwar Kamal Kant Arya; Deepak Kumar; Sushil Kumar Chaudhary; Vijay Singh Rana; Neeraj K Sethiya
Journal:  Phytomed Plus       Date:  2021-12-18

Review 4.  The Role of Herbal and Nutritional Treatments in the Fight against COVID-19 and Other Respiratory Tract Infections.

Authors:  Aline El Zakhem; May Annie Chalhoub; Maya Bassil
Journal:  Int J Environ Res Public Health       Date:  2021-11-16       Impact factor: 3.390

Review 5.  Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.

Authors:  Adel A Gomaa; Yasmin A Abdel-Wadood; Mohamed A Gomaa
Journal:  Inflammopharmacology       Date:  2022-09-22       Impact factor: 5.093

6.  Glycyrrhizin through liquorice intake modulates ACE2 and HMGB1 levels-A pilot study in healthy individuals with implications for COVID-19 and ARDS.

Authors:  Felix Buder; Simina-Ramona Selejan; Mathias Hohl; Michael Kindermann; Christian Herr; Philipp M Lepper; Robert Bals; Bernd Salzberger; Felix Mahfoud; Michael Böhm
Journal:  PLoS One       Date:  2022-10-17       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.